Revised Self-Monitoring Scale: A potential endpoint for frontotemporal dementia clinical trials.

Gianina TollerKamalini RanasingheYann CobigoAdam StaffaroniBrian ApplebyDanielle BrushaberGiovanni CoppolaBradford C DickersonKimiko Domoto-ReillyJulie FieldsJamie C FongLeah ForsbergNupur GhoshalNeill Graff-RadfordMurray GrossmanHilary HeuerGing-Yuek Robin HsiungEdward HueyDavid IrwinKejal KantarciDaniel KauferDiana KerwinDavid KnopmanJohn KornakJoel KramerIrene LitvanIan MackenzieMario MendezBruce MillerRosa RademakersEliana RamosKatya RascovskyErik D RobersonJeremy SyrjanenCarmela TartagliaSandra WeintraubBrad BoeveAdam BoxerHoward RosenKatherine Rankinnull null

Published in: Neurology (2020)

The RSMS is sensitive to progression of both socioemotional symptoms and SN atrophy in patients with bvFTD and corresponds directly to caregiver burden. The RSMS may be useful in both neurologic practice and clinical trials aiming to treat behavioral symptoms of patients with bvFTD.

Keyphrases

clinical trial
phase ii
primary care
healthcare
sleep quality
open label
double blind
phase iii
risk factors
randomized controlled trial
quality improvement